新規でNeurology系の何かを準備中かな。

GPR52 accelerates fatty acid biosynthesis in a ligand-dependent manner in hepatocytes and in response to excessive fat intake in mice repository.kulib.kyoto-u.ac.jp/server/api/cor…

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1 takeda.com/newsroom/newsr…

Takeda’s narcolepsy blockbuster hopeful secures double phase 3 wins, teeing up FDA filing fiercebiotech.com/biotech/takeda…

Stabilized D2R G-protein coupled receptor oligomers identify 2 multi-state β-arrestin complexes biorxiv.org/content/10.110…

Glutathione oxidation in cerebrospinal fluid as a biomarker of oxidative stress in amyotrophic lateral sclerosis …alneurodegeneration.biomedcentral.com/articles/10.11…

Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025 biospace.com/press-releases…

Structure-guided engineering of snake toxins for selective modulation of adrenergic and muscarinic receptors nature.com/articles/s4146…

Why are VHHs the best choice for antibody engineering? isogenica.com/faqs/

Unlocking Hard-to-Drug Targets: How VHH Antibodies Overcome Drug Discovery Barriers isogenica.com/hard-to-drug-t…

Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy nature.com/articles/s4155… fusion proteins composed of a nanobody that recognizes immunoglobulin kappa light chains (VHHkappa) and a nanobody that recognizes either CTLA-4 or PD-L1.

Manufacturing Scale Up of Lead Ox-1 Development Programme otp.tools.investis.com/clients/uk/evg…

The mechanosensitive adhesion G protein-coupled receptor133 (GPR133/ADGRD1) enhances bone formation nature.com/articles/s4139… GPR133/ADGRD1 as a promisingtherapeutic target for osteoporosis and other diseases characterized by reduced bone mass.

This is a *pretty amazing* paper--really fascinating implications for those who wish the field would finally begin to look into #cellbio cell.com/cell-metabolis…

The role of M3-muscarinic receptor signaling in insulin secretion pmc.ncbi.nlm.nih.gov/articles/PMC31…

M3 agonistとかもやっているのかな。

De novo design of a fusion protein tool for GPCR research pnas.org/doi/10.1073/pn…

Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders draigtherapeutics.com/wp-content/upl… DT-101, a next-generation AMPA receptor PAM into Phase 2 trials in 2025